AI Article Synopsis

  • L-Dopa is the main treatment for Parkinson's disease, but its effectiveness is limited by short duration and inconsistent blood levels, leading to difficulties in managing symptoms.
  • A new decentralized testing method using a disposable biosensor strip allows for quick and cost-effective measurement of L-Dopa from capillary blood, enabling real-time monitoring of drug levels.
  • The pilot study shows a strong correlation between capillary L-Dopa levels and motor symptoms, indicating that this biosensing technology can help personalize L-Dopa dosing for better symptom control and improved quality of life for patients.

Article Abstract

While levodopa (L-Dopa) is the primary treatment for alleviating Parkinson's disease (PD), its efficacy is hindered by challenges such as a short half-life and inconsistent plasma levels. As PD progresses, the rising need for increased and more frequent L-Dopa doses coupled with symptom fluctuations and dyskinesias underscores the urgency for improved comprehension of the interplay between L-Dopa levels and PD motor symptoms. Addressing this critical need, we present a decentralized testing method using a disposable biosensor strip and a universal slope (U-slope) calibration-free approach. This enables reliable, rapid, simple, and cost-effective decentralized L-Dopa measurements from capillary blood. A pilot study with PD persons demonstrates the ability to monitor real-time L-Dopa pharmacokinetics from fingerstick blood after oral L-Dopa-Carbidopa (C-Dopa) tablet administration. Correlating capillary blood L-Dopa levels with PD motor scores revealed a well-defined inverse correlation with temporal motor fluctuations. We compared the resulting dynamic capillary blood L-Dopa levels with plasma L-Dopa levels using the traditional but clinically impractical high-performance liquid chromatography technique. By providing timely feedback on a proper L-Dopa dosing regimen in a decentralized and rapid fashion, this new biosensing platform will facilitate tailored optimal L-Dopa dosing, towards improving symptom management and enhancing health-related quality of life.

Download full-text PDF

Source
http://dx.doi.org/10.1002/anie.202403583DOI Listing

Publication Analysis

Top Keywords

l-dopa levels
16
capillary blood
12
l-dopa
10
biosensor strip
8
parkinson's disease
8
levels motor
8
blood l-dopa
8
l-dopa dosing
8
levels
5
strip rapid
4

Similar Publications

Ethylenediamine assist preparation of carbon dots with novel biomass for highly sensitive detection of levodopa.

RSC Adv

January 2025

Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Collaborative Innovation Center of One Health, Hainan University Haikou 570228 China

Levodopa (l-Dopa), a precursor drug for dopamine has been widely used to treat Parkinson's disease. However, excess accumulation of l-Dopa in the body may cause movement disorders and uncontrollable emotions. Therefore, it is vital to monitor l-Dopa levels in patients.

View Article and Find Full Text PDF

Alexithymia in Parkinson's Disease: A Meta-analysis.

Am J Geriatr Psychiatry

December 2024

HM CINAC (Centro Integral de Neurociencias Abarca Campal) (RFF, CDTP, CGS), Hospital Universitario HM Puerta del Sur, HM Hospitales. Madrid, Spain; Instituto de Investigación Sanitaria HM Hospitales (RFF, CDTP, CGS), Madrid, Spain; Network Center for Biomedical Research on Neurodegenerative Diseases (CIBERNED) (CGS), Instituto Carlos III, Madrid, Spain; University CEU-San Pablo (CGS), Madrid, Spain. Electronic address:

Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor and non-motor manifestations, including alexithymia. This condition is defined by difficulty in recognizing, articulating, and expressing one's emotional states. In this study, we conducted a systematic review and meta-analysis to compare the prevalence of alexithymia in PD patients and a healthy population, and to identify associated demographic and clinical factors.

View Article and Find Full Text PDF

High-efficiency production of plant-derived pigment dopaxanthin in Escherichia coli by combination engineering.

Microb Cell Fact

December 2024

Key Laboratory of Engineering Biology for Low-carbon Manufacturing, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, 300308, China.

Background: Dopaxanthin is a natural pigment betaxanthins family member with the highest antioxidant and free radical scavenging activities. However, its relatively low content in plants limited the wide range of applications. Cost-efficient microbial production, therefore, showed an attractive alternative.

View Article and Find Full Text PDF

The present study investigates the neuroprotective effects of the sea urchin Paracentrotus lividus gonadal extract on rotenone-induced neurotoxicity in a Parkinson's disease (PD) rat model. Parkinson's disease, characterized by the progressive loss of dopaminergic neurons in the substantia nigra (SN), is exacerbated by oxidative stress and neuroinflammation. The study involved fifty Wistar rats divided into five groups: control, dimethyl sulfoxide (DMSO) control, Paracentrotus lividus gonadal extract-treated, rotenone-treated, and combined rotenone with Paracentrotus lividus gonadal extract-treated.

View Article and Find Full Text PDF

Serum neurofilament light chain as a diagnostic and prognostic biomarker in multiple system atrophy: a prospective cohort study.

J Neurol

December 2024

Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital Capital Medical University, Beijing Institute of Geriatrics, 45 Changchun Street, Xicheng District, Beijing, 100053, China.

Background: Neurofilament light chain (NFL) in blood has been identified as a valuable biomarker in multiple system atrophy (MSA), but data regarding its utility in the early diagnosis and prognosis of MSA remain limited.

Objective: To investigate serum NFL's diagnostic and prognostic value in patients with MSA in a prospective clinical cohort.

Methods: Two hundred twenty-eight participants were enrolled, including ninety-eight with MSA, seventeen with uncertain MSA at inclusion, fifty-nine with Parkinson's disease (PD), and fifty-four healthy controls (HCs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!